Investment Thesis
Modular Medical faces an existential cash crisis with operating cash burn of $23.8M annually and only $6.9M in cash reserves (approximately 3 months runway). The combination of zero gross profit on $16M revenue, -$28.2M net loss, and -$27.7M free cash flow indicates fundamental operational failure or severe data quality issues. Without immediate capital infusion or dramatic operational restructuring, the company faces imminent solvency risk.
Strengths
- Strong liquidity position with 4.03x current ratio providing short-term cushion
- Zero long-term debt eliminates leverage risk and provides flexibility for restructuring
- Operates in medical devices sector with potential for high-margin products if operational issues resolved
Risks
- Critical cash runway of <3 months at current burn rate of -$27.7M FCF annually
- Zero gross profit on $16M revenue indicates products sold at loss or fundamental business model failure
- Massive operating losses (-$27.6M) with no clear path to profitability suggest unsustainable cost structure
- Negative ROE (-217.9%) and ROA (-190.4%) indicate severe shareholder value destruction
- Likely requires immediate capital raise which will cause significant equity dilution
Key Metrics to Watch
- Operating cash flow trend and monthly burn rate (current -$23.8M is unsustainable)
- Gross profit reconciliation - zero margin requires investigation for accounting or operational issues
- Cash balance decline rate and timeline to funding event
- Revenue quality and product-level gross margins breakdown
Financial Metrics
Revenue
16.0
Net Income
-28.2M
EPS (Diluted)
$-12.36
Free Cash Flow
-27.7M
Total Assets
14.8M
Cash
6.9M
Profitability Ratios
Gross Margin
0.0%
Operating Margin
-172,250,000.0%
Net Margin
-176,512,500.0%
ROE
-217.9%
ROA
-190.4%
FCF Margin
-173,031,250.0%
Balance Sheet & Liquidity
Current Ratio
4.03x
Quick Ratio
4.03x
Debt/Equity
0.00x
Debt/Assets
12.6%
Interest Coverage
-10.01x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-07-29T06:04:40.722810 |
Data as of: 2026-03-31 |
Powered by Claude AI